EUVIMEDEUVIMED entdecken
Crossref

Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No

Fred Saad

European Urology Focus · 2024

DOI: 10.1016/j.euf.2024.07.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2024. Verfasst von Fred Saad. Beteiligte Einrichtung: Department of Surgery, University of Montreal Hospital Center, Montreal, Canada. Electronic address: fred.saad@umontreal.ca. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients who benefit the most from combinations of an androgen receptor pathway inhibitor and a PARP inhibitor are those with a BRCA mutation, but there are certainly patients without BRCA mutations who will benefit from this treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsProstatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsMutationHumansMaleReceptors, AndrogenGenes, BRCA1Antineoplastic Combined Chemotherapy ProtocolsGenes, BRCA2BRCA2 Protein

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsAndrogen Receptor AntagonistsReceptors, AndrogenBRCA2 Protein

Autor:innen und Institutionen

  • Department of Surgery, University of Montreal Hospital Center, Montreal, Canada. Electronic address: fred.saad@umontreal.ca.

Zitieren

APA

Saad, F. (2024). Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No. European Urology Focus. https://doi.org/10.1016/j.euf.2024.07.015

Vancouver

Saad F. Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No. European Urology Focus. 2024. doi:10.1016/j.euf.2024.07.015

BibTeX
@article{Saad2024,
  author = {Saad, Fred},
  title = {Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No},
  journal = {European Urology Focus},
  year = {2024},
  doi = {10.1016/j.euf.2024.07.015}
}
Kostenlos starten →